

Trans #	Acquiring	Acquired	Entities
20050117	Estate of Ernest L. Samuel	Mr. Charles E. Pompea	Primac Corp., Primary Steel, Inc., Primtech LLC
TRANSACTIONS GRANTED EARLY TERMINATION—11/04/2004			
20050020	PacifiCare Health Systems, Inc	American Medical Security Group, Inc.	American Medical Security Group, Inc.
20050039	J. W. Childs Equity Partners, III, L.P	Vestar Capital Partners, III, L.P	Sheridan Holdings, Inc.
20050069	AFFC Holdings, Inc	BP p.l.c	Amoco Fabrics and Fibers Company, BP Corporation North America Inc.
20050087	ViroPharma Incorporated	Eli Lilly and Company	Eli Lilly and Company.
TRANSACTIONS GRANTED EARLY TERMINATION—11/05/2004			
20050073	Worley Group Limited	Parsons Employee Stock Ownership Plan.	Parsons E&C Corporation
20050104	Raul Alarcon, Jr	Sumner M. Redstone	Infinity Broadcasting Corporation of San Francisco
20050105	CompuCredit Corporation	Dennis M. Mathisen	BANKFIRST.
20050114	Atlantic Power Corporation	Teton Power Holdings, LLC	Onondaga Cogeneration Limited Partnership, Split Rock Holdings, LLC, Topsham Hydroelectric Generating Facility.
20050115	Atlantic Power Corporation	ArcLight Energy Partners Fund II, L.P.	Umatilla Power Funding, LLC
20050122	Cypress Merchant Banking Partners II L.P.	Stone Canyon Entertainment Corp	Stone Canyon Entertainment Corp.
20050129	Ryerson Tull, Inc	Alcoa Inc	Integrus Metals, Inc.
TRANSACTIONS GRANTED EARLY TERMINATION—11/08/2004			
20050113	Southern Wine & Spirits of America, Inc.	David Taub	Darmart Enterprises, Inc., Gallo Wines Distributors, L.L.C. d/b/a, Premier Wines & Spirit, New York Depot Distributing Co., LLC.
20050125	United Online, Inc	Classmates Online, Inc	Classmates Online, Inc.
20050126	Warburg Pincus Private Equity VIII, L.P.	Avicis, Inc	Avicis, Inc.
20050127	World Directories S.a.r.l. ("WDS")	VNU N.V	VNU World Directories Inc.
20050128	Ryerson Tull, Inc	BHP Billiton Pic	Integrus Metals, Inc.
20050130	Rush Enterprises, Inc	Jesse and Milo Kirk	American Truck Source, Inc.
20050131	J.P. Morgan Chase & Co	Michael Hirtenstein	WestCom Corporation
20050133	Centene Corporation	Swope Community Enterprises	FirstGuard Health Plan, Inc., FirstGuard, Inc.
20050134	Auto Sueco, Lda	Aktiebolaget Volvo	SABA Holding Company.
20050135	CharterMac	Capri Realty Capital, LLC	Capri Capital Limited Partnership
20050138	KeyCorp	American Express Company	American Express Business Finance Corporation
TRANSACTIONS GRANTED EARLY TERMINATION—11/09/2004			
20050066	Armor Holdings, Inc	The Specialty Group, Inc	The Specialty Group, Inc.
20050120	Fuji Photo Film Co., Ltd	Arch Chemicals, Inc	Arch Chemical Specialties Products, Inc., Arch Electronic Chemicals, Inc., Arch Specialty Chemicals, Inc.

FOR FURTHER INFORMATION CONTACT:

Sandra M. Peay, Contact Representative, or Renee Hallman, Case Management Assistant, Federal Trade Commission, Premerger Notification Office, Bureau of Competition, Room H-303, Washington, DC 20580, (202) 326-3100.

By direction of the Commission.

Donald S. Clark,
Secretary.

[FR Doc. 04-26938 Filed 12-7-04; 8:45 am]

BILLING CODE 6750-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES**Centers for Disease Control and Prevention**

[30Day-05-0138]

Proposed Data Collections Submitted for Public Comment and Recommendations

The Centers for Disease Control and Prevention (CDC) publishes a list of information collection requests under

review by the Office of Management and Budget (OMB) in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these requests, call the CDC Reports Clearance Officer at (404) 498-1210 or send an email to omb@cdc.gov. Send written comments to CDC Desk Officer, Human Resources and Housing Branch, New Executive Office Building, Room 10235, Washington, DC 20503 or by fax to (202) 395-6974. Written comments should be received within 30 days of this notice.

Proposed Project

Pulmonary Function Testing Course Approval Program, 29 CFR 1910.1043, OMB No. 0920-0138—Revision—National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention (CDC).

NIOSH has the responsibility under the Cotton Dust Standard, 29 CFR 1920.1043, for approving courses to train technicians to perform pulmonary function testing in the Cotton Dust Industry. Successful completion of a NIOSH-approved course is mandatory under the Standard. To carry out its responsibility, NIOSH maintains a Pulmonary Function Testing Course

Approval Program. The program consists of an application submitted by potential sponsors who seek NIOSH approval to conduct courses. The application form and added materials, including an agenda, vitae, and course materials are reviewed by NIOSH to determine if the applicant has developed a program which adheres to the criteria required in the Standard. Following approval, any subsequent changes to the course are submitted by course sponsors via letter or e-mail and reviewed by NIOSH staff to assure that the changes in faculty or course content continue to meet course requirements.

Course sponsors also voluntarily submit an annual report to inform

NIOSH of their class activity level and if any faculty changes have occurred. Applications and materials to be a course sponsor and carry out training are submitted voluntarily by institutions and organizations throughout the country. This is required by NIOSH to evaluate a course to determine whether it meets the criteria in the Standard and whether technicians will be adequately trained as mandated under the Standard. One question regarding faculty changes was added to the previously approved annual report. There will be no cost to respondents except their time to participate. The estimated annualized burden is 64 hours.

ANNUALIZED BURDEN TABLE

Respondents	Number of respondents	Number of responses/ respondents	Average burden/ response (in hrs)
Initial Application	5	1	3.5
Annual Report	50	1	45/60
Report for Course Changes	12	1	45/60

Dated: November 29, 2004.

B. Kathy Skipper,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 04-26913 Filed 12-7-04; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[7Day-05-AN]

Proposed Data Collections Submitted for Public Comment and Recommendations

In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 for opportunity for public comment on proposed data collection projects, the Centers for Disease Control and Prevention (CDC) will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the data collection plans and instruments, call the CDC Reports Clearance Officer at (404) 498-1210. CDC is requesting an emergency clearance for this data collection with a seven-day public comment period. CDC is requesting OMB approval of this package seven days after the end of the public comment period.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. As this is an emergency clearance, please direct comments to the CDC Desk Officer, Human Resources and Housing Branch, New Executive Office Building, Room 10235, Washington, DC 20503 or by fax to (202) 395-6974. Comments should be received within seven days of this notice.

Proposed Project: Performance Evaluation Program for Severe Acute Respiratory Syndrome Antibody (SARS Ab) Testing—New—Public Health Practice Program Office (PHPPO), Centers for Disease Control and Prevention (CDC).

Great attention has been focused on SARS which is a viral respiratory illness caused by a coronavirus, called SARS-associated coronavirus (SARS-CoV). SARS was first reported in Asia in February 2003. Over the next few months, the illness spread to more than

two dozen countries in North America, South America, Europe, and Asia before the SARS global outbreak of 2003 was contained.

The SARS virus has recently been shown to be endemic in some populations, and as the season most conducive for SARS infection approaches, the possibility for an outbreak or epidemic exists. Therefore, it is imperative that the CDC ensure all State Public Health laboratories and other laboratories designated by CDC remain proficient in performing SARS testing. For this reason, it is of critical public health importance, at this time, that the CDC develop and maintain a performance evaluation program for SARS.

CDC, through the Model Performance Evaluation Program (MPEP), intends to provide a new SARS-CoV testing performance evaluation program (SARS MPEP). This program will offer external performance evaluation for SARS Ab testing. Participation in the performance evaluation program is expected to lead to improved SARS testing performance because participants have the opportunity to identify areas for improvement. This will help ensure accurate testing as a basis for development of SARS prevention and intervention strategies.

This external quality assessment program will be made available at no cost (for receipt of sample panels) to 44 state laboratories. Participants in the